Literature DB >> 2953165

Dopamine receptor properties in Parkinson's disease and Huntington's chorea evaluated by positron emission tomography using 11C-N-methyl-spiperone.

J Hägglund, S M Aquilonius, S A Eckernäs, P Hartvig, H Lundquist, P Gullberg, B Långström.   

Abstract

Dopaminergic receptor properties in the striatum of patients with Parkinson's disease (PD) and Huntington's chorea (HD) were studied by positron emission tomography (PET), using 11C-N-methyl-spiperone as a dopamine D2 receptor ligand. The time-dependent regional radioactive uptake in the caudate nucleus and the putamen was measured and fitted to a 3-compartment pharmacokinetic model. The rate constant k3 for specific binding to the receptor compartment in the striatum was determined in relation to the binding in regions with a low density of specific binding sites, such as the cerebellum and the frontal cortex . k3, which is a measure of the receptor density, was reduced in one patient with HD but less affected in PD in comparison with healthy controls. The pattern of k3 values calculated from the 6 PD patients is discussed in relation to any side-to-side differences in dopamine receptor densities in hemiparkinsonism and to possible "hypersensitivity" of dopamine receptors in the early stage of the disease and down-regulation in more advanced disease.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2953165     DOI: 10.1111/j.1600-0404.1987.tb07900.x

Source DB:  PubMed          Journal:  Acta Neurol Scand        ISSN: 0001-6314            Impact factor:   3.209


  14 in total

Review 1.  PET and movement disorders.

Authors:  D J Brooks; R S Frackowiak
Journal:  J Neurol Neurosurg Psychiatry       Date:  1989-06       Impact factor: 10.154

Review 2.  Positron emission tomography imaging of transplant function.

Authors:  David J Brooks
Journal:  NeuroRx       Date:  2004-10

3.  Positron emission tomography studies of neurotransmitter systems.

Authors:  G V Sawle; D J Brooks
Journal:  J Neurol       Date:  1990-12       Impact factor: 4.849

4.  Striatal dopamine receptor occupancy during and following withdrawal from neuroleptic treatment: correlative evaluation by positron emission tomography and plasma prolactin levels.

Authors:  J C Baron; J L Martinot; H Cambon; J P Boulenger; M F Poirier; V Caillard; J Blin; J D Huret; C Loc'h; B Maziere
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

Review 5.  Imaging the head: functional imaging.

Authors:  G V Sawle
Journal:  J Neurol Neurosurg Psychiatry       Date:  1995-02       Impact factor: 10.154

Review 6.  Where have we got to with neuroreceptor mapping of the human brain?

Authors:  B Mazière; M Mazière
Journal:  Eur J Nucl Med       Date:  1990

Review 7.  Functional imaging in Huntington's disease.

Authors:  Jane S Paulsen
Journal:  Exp Neurol       Date:  2009-01-03       Impact factor: 5.330

8.  Dopamine D1 receptor number--a sensitive PET marker for early brain degeneration in Huntington's disease.

Authors:  G Sedvall; P Karlsson; A Lundin; M Anvret; T Suhara; C Halldin; L Farde
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1994       Impact factor: 5.270

9.  Regulation of dopamine D₃ receptor in the striatal regions and substantia nigra in diffuse Lewy body disease.

Authors:  J Sun; N J Cairns; J S Perlmutter; R H Mach; J Xu
Journal:  Neuroscience       Date:  2013-06-01       Impact factor: 3.590

10.  Striatal blood flow, glucose metabolism and 18F-dopa uptake: difference in Parkinson's disease and atypical parkinsonism.

Authors:  M Otsuka; Y Ichiya; S Hosokawa; Y Kuwabara; T Tahara; T Fukumura; M Kato; K Masuda; I Goto
Journal:  J Neurol Neurosurg Psychiatry       Date:  1991-10       Impact factor: 10.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.